|Bid||0.00 x 0|
|Ask||84.97 x 100|
|Day's Range||78.05 - 78.52|
|52 Week Range||64.18 - 86.72|
|PE Ratio (TTM)||37.79|
|Dividend & Yield||2.08 (2.66%)|
|1y Target Est||N/A|
Of the 21 analysts tracking Merck in August 2017, three analysts recommended a “strong buy,” and ten analysts recommended a “buy.” Seven analysts recommended a "hold," and one analyst recommended ...
Incyte (INCY) distributes its key drug, Jakafi, through its own network of specialty pharmacy providers and wholesalers in US markets.
Incyte’s (INCY) product portfolio includes targeted therapies and immunotherapies for oncology as well as non-oncology products.